Wednesday, May 25, 2011

Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions

New Interim Results from the PRESERVE Study Evaluate ENBREL Therapy in Patients with Moderately Active Rheumatoid Arthritis

Analysis of Ankylosing Spondylitis Trials Suggests Nocturnal Back Pain is Predictive of Fatigue, and ENBREL was Shown to Reduce These Symptoms

PRISTINE Trial Data Explore Effects of ENBREL on Cardiometabolic Biomarkers in Subjects with Moderate-to-Severe Plaque Psoriasis

THOUSAND OAKS, Calif. and NEW YORK, May 25, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced new results from multiple studies of ENBREL, further expanding the body of evidence supporting the efficacy and safety profile of ENBREL, the most prescribed biologic by rheumatologists in the United States (U.S.). Eighteen abstracts across four indications, including moderate-to-severe rheumatoid arthritis (RA), ankylosing spondylitis (AS), moderate-to-severe plaque psoriasis (PsO), and psoriatic arthritis (PsA), will be published at two global medical congresses, the European League Against Rheumatism (EULAR) and World Congress of Dermatology (WCD), this week.

Read the rest of this entry

Posted in Press Releases

Friday, May 20, 2011

Amgen Announces Voting Results Of Annual Meeting of Stockholders

SEATTLE, May 20, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN), today announced results of voting at the Company’s Annual Meeting of Stockholders, held at The Fairmont Olympic Hotel in Seattle, Wash. Approximately 86.32 percent of outstanding shares were represented at the meeting.

Read the rest of this entry

Posted in Press Releases

Friday, May 20, 2011

Amgen Receives CHMP Positive Opinion for XGEVA™ (Denosumab) in the European Union

Positive Opinion Based on Largest Clinical Program Ever Conducted in Patients with Bone Metastases

THOUSAND OAKS, Calif., May 20, 2011 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a positive opinion for the marketing authorization of XGEVA™ (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors. If approved by the European Commission, Amgen would receive marketing authorization for XGEVA in all European Union (EU) Member States. The CHMP also recommended to grant XGEVA an additional year of data and market exclusivity in the EU since the indication was considered significantly new for XGEVA, and based on the significant clinical benefit of the product in comparison with existing therapies.

Bone metastases, the spread of cancer to the bones, are a common and serious concern for patients with advanced cancer and present a burden to the healthcare system. Weakened bones due to metastases can lead to fractures and compression of the spinal cord and necessitate procedures like major surgery and radiation, collectively called skeletal-related events (SREs). The primary goal of treatment for bone metastases is to prevent the occurrence of these debilitating and costly SREs.

Read the rest of this entry

Posted in Press Releases

Wednesday, May 18, 2011

Amgen Oncology Data to be Presented at ASCO Annual Meeting

THOUSAND OAKS, Calif., May 18, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced that data from studies involving nine Amgen products will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3 - 7, 2011 in Chicago. These studies include data from the XGEVA® (denosumab), Vectibix® (panitumumab), ganitumab (AMG 479) and AMG 386 programs.

Read the rest of this entry

Posted in Press Releases

Tuesday, May 17, 2011

Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer

Study Meets Primary Endpoint by Significantly Improving Bone Metastasis-Free Survival for More Than Four Months

Up to 90 Percent of Men with Advanced Prostate Cancer Will Develop Bone Metastases

THOUSAND OAKS, Calif., May 17, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced primary results of a pivotal Phase 3 trial (’147) demonstrating that XGEVA™ (denosumab) significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone.  Full results of the ‘147 study were presented for the first time today in a late-breaking plenary session at the American Urological Association (AUA) 2011 Annual Meeting in Washington, D.C.

Read the rest of this entry

Posted in Press Releases